Literature DB >> 19918338

Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.

Elisabeth Eckersberger1, Julia Finkelstein, Helen Sadri, Markus Margreiter, Samir S Taneja, Herbert Lepor, Bob Djavan.   

Abstract

The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality: the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Entities:  

Keywords:  European Randomized Study of Screening for Prostate Cancer (ERSPC); PSA screening; Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Year:  2009        PMID： 19918338      PMCID： PMC2777060     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  21 in total

1.  Prostate cancer: to screen or not to screen?

Authors:  Urs E Studer; Laurence Collette
Journal:  Nat Rev Urol       Date:  2009-06       Impact factor: 14.432

2.  Annual screening for prostate cancer did not reduce mortality from prostate cancer.

Authors:  Steven E Canfield
Journal:  Evid Based Med       Date:  2009-08

3.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort.

Authors:  C J Newschaffer; K Otani; M K McDonald; L T Penberthy
Journal:  J Natl Cancer Inst       Date:  2000-04-19       Impact factor: 13.506

4.  American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection.

Authors:  R A Smith; A C von Eschenbach; R Wender; B Levin; T Byers; D Rothenberger; D Brooks; W Creasman; C Cohen; C Runowicz; D Saslow; V Cokkinides; H Eyre
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

5.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Authors:  René Raaijmakers; Wim J Kirkels; Monique J Roobol; Mark F Wildhagen; Fritz H Schrder
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

Review 6.  Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen.

Authors:  R A Stephenson; J L Stanford
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

7.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Authors:  B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan
Journal:  J Natl Cancer Inst       Date:  1999-06-16       Impact factor: 13.506

8.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

9.  Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.

Authors:  Harmon Eyre; Richard Kahn; Rose Marie Robertson; Nathaniel G Clark; Colleen Doyle; Yuling Hong; Ted Gansler; Thomas Glynn; Robert A Smith; Kathryn Taubert; Michael J Thun
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

10.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.

Authors:  H B Carter; J I Epstein; A W Partin
Journal:  Urology       Date:  1999-01       Impact factor: 2.649
View more
  22 in total

Review 1.  The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.

Authors:  Matt T Rosenberg; David Staskin; John Riley; Grannum Sant; Martin Miner
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 2.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

3.  Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group.

Authors:  Cindy Ke Zhou; David P Check; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Jacques Ferlay; Freddie Bray; Michael B Cook; Susan S Devesa
Journal:  Int J Cancer       Date:  2015-11-27       Impact factor: 7.396

4.  Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression.

Authors:  Julie V Philley; Anbarasu Kannan; Wenyi Qin; Edward R Sauter; Mitsuo Ikebe; Kate L Hertweck; Dean A Troyer; Oliver J Semmes; Santanu Dasgupta
Journal:  J Cell Physiol       Date:  2015-11-24       Impact factor: 6.384

5.  Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression.

Authors:  Junyi Chen; Li Jiao; Chuanliang Xu; Yongwei Yu; Zhensheng Zhang; Zheng Chang; Zhen Deng; Yinghao Sun
Journal:  BMC Cancer       Date:  2012-12-11       Impact factor: 4.430

6.  The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression.

Authors:  Caroline Schroten; Natasja F Dits; Ewout W Steyerberg; Ries Kranse; Arno G J L H van Leenders; Chris H Bangma; Robert Kraaij
Journal:  Cancer Immunol Immunother       Date:  2011-11-24       Impact factor: 6.968

7.  A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.

Authors:  Dean A Troyer; Tamara Jamaspishvili; Wei Wei; Ziding Feng; Jennifer Good; Sarah Hawley; Ladan Fazli; Jesse K McKenney; Jeff Simko; Antonio Hurtado-Coll; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; James D Brooks; Jeremy A Squire
Journal:  Prostate       Date:  2015-05-04       Impact factor: 4.104

8.  Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing.

Authors:  Sanny Kappen; Geertruida H de Bock; Eunice Sirri; Claudia Vohmann; Joachim Kieschke; Alexander Winter
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

9.  Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010.

Authors:  Therese Lloyd; Luke Hounsome; Anita Mehay; Sarah Mee; Julia Verne; Alison Cooper
Journal:  BMC Med       Date:  2015-07-30       Impact factor: 8.775

10.  Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey.

Authors:  Sanny Kappen; Verena Jürgens; Michael H Freitag; Alexander Winter
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.